Human embryonic stem cell-derived dopaminergic cells for Parkinson's disease: a phase 1/2 open-label trial.

Paul G, Bjartmarz H, Kirkeby A, Nelander J, Smith R, Kayhanian S, Evans A, Harry B, Cutting E, Fazal S, Lao-Kaim NP, van Vliet T, Ullén S, Grubor I, Hansson O, Piccini P, Lindvall O, Björklund A, Widner H, Parmar M, Barker RA

Open source

DOI
10.1038/s41591-026-04525-0
Published
2026 Sep
Container
Nature medicine
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1038/s41591-026-04525-0,
  title = {Human embryonic stem cell-derived dopaminergic cells for Parkinson's disease: a phase 1/2 open-label trial.},
  author = {Paul G and Bjartmarz H and Kirkeby A and Nelander J and Smith R and Kayhanian S and Evans A and Harry B and Cutting E and Fazal S and Lao-Kaim NP and van Vliet T and Ullén S and Grubor I and Hansson O and Piccini P and Lindvall O and Björklund A and Widner H and Parmar M and Barker RA},
  year = {2026},
  journal = {Nature medicine},
  doi = {10.1038/s41591-026-04525-0},
  url = {https://doi.org/10.1038/s41591-026-04525-0}
}

RIS

TY  - JOUR
TI  - Human embryonic stem cell-derived dopaminergic cells for Parkinson's disease: a phase 1/2 open-label trial.
AU  - Paul G
AU  - Bjartmarz H
AU  - Kirkeby A
AU  - Nelander J
AU  - Smith R
AU  - Kayhanian S
AU  - Evans A
AU  - Harry B
AU  - Cutting E
AU  - Fazal S
AU  - Lao-Kaim NP
AU  - van Vliet T
AU  - Ullén S
AU  - Grubor I
AU  - Hansson O
AU  - Piccini P
AU  - Lindvall O
AU  - Björklund A
AU  - Widner H
AU  - Parmar M
AU  - Barker RA
PY  - 2026
JO  - Nature medicine
DO  - 10.1038/s41591-026-04525-0
UR  - https://doi.org/10.1038/s41591-026-04525-0
ER  - 

APA

G, P., H, B., A, K., J, N., R, S., S, K., A, E., B, H., E, C., S, F., NP, L., T, V. V., S, U., I, G., O, H., P, P., O, L., A, B., H, W., M, P., & RA, B. (2026). Human embryonic stem cell-derived dopaminergic cells for Parkinson's disease: a phase 1/2 open-label trial.. Nature medicine. https://doi.org/10.1038/s41591-026-04525-0

Source records